Chinese Biotech Firm Ascletis Leads Series E Round In American Pharma 3-V Biosciences

Login to View

An affiliate of Hong Kong-listed Chinese biotech company Ascletis Pharma has led a US$18 million series E financing round in San Francisco-based clinical-stage pharmaceutical firm 3-V Biosciences, said Ascletis in a statement released on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in